Product Description
Mechanisms of Action: H1 Antagonist, Calcium Channel Blocker
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | China | Colombia | Denmark | Dominican Republic | Ecuador | Egypt | France | Germany | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Italy | Jordan | Korea | Lebanon | Luxembourg | Malaysia | Malta | Mexico | Netherlands | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Saudi Arabia | Singapore | Slovenia | South Africa | Spain | Sri Lanka | Switzerland | Taiwan | Turkey | United Kingdom | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: Eastern America
Company Founding Year: 1849
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07445464 |
ASP-001-01 | P1 |
Not yet recruiting |
Healthy Volunteers |
2026-06-02 |
88% |
2026-03-04 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
03/10/2026 |
News Article |
Unit21 Relaunches as the Leader in AI Risk Infrastructure |
|
03/10/2026 |
News Article |
Atomic Minerals Completes Airborne Gradient Magnetometer Survey at Mozzie Lake Uranium Project |
|
03/10/2026 |
News Article |
Quantro Security Emerges from Stealth to Reinvent Cyber Defense with Autonomous AI Agents |
|
03/03/2026 |
News Article |
Gradient Geothermal Supporting First-in-the-Nation Colorado Initiative to Transform Orphan Oil & Gas Wells into Geothermal and Carbon Storage Assets |